All Updates

All Updates

icon
Filter
Funding
OnKure Therapeutics raises USD 54 million in Series C funding
Precision Medicine
May 23, 2023
This week:
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Funding
OceanWell raises USD 11 million in Series A funding to build water farms
Conservation Tech
Yesterday
Product updates
H launches Runner H, an AI agent for business automation
Foundation Models
Yesterday
Partnerships
Capgemini partners with Mistral AI and Microsoft to expand GenAI solutions globally
Foundation Models
Yesterday
Funding
Product updates
Converge Bio launches biotech LLM platform with USD 5.5 million seed funding
Foundation Models
Yesterday
Partnerships
Snowflake partners with Anthropic to integrate Claude AI models into Cortex AI platform
Foundation Models
Yesterday
Product updates
DeepSeek releases AI reasoning model DeepSeek-R1
Foundation Models
Yesterday
Industry news
Partnerships
ICEYE partners with Lockheed Martin and Finnish firms to develop defense space technologies
Next-gen Satellites
Yesterday
Partnerships
Dematic installs AutoStore system at South West Healthcare logistics hub
Logistics Tech
Yesterday
Precision Medicine

Precision Medicine

May 23, 2023

OnKure Therapeutics raises USD 54 million in Series C funding

Funding

  • Colorado-based drug discovery and developer OnKure Therapeutics raised USD 54 million in a Series C funding round led by Surveyor Capital, with participation from Deep Track Capital, Acorn Bioventures, Cormorant Asset Management, Perceptive Advisors, Samsara BioCapital, BlackRock, and other undisclosed investors. This brings the total funds raised to USD 121.5 million.

  • The funds will be used to support the development of OnKure's pipeline of precision medicines, including advancing its lead discovery program, OKI-219, into clinical development.

  • OnKure is a clinical-stage biopharmaceutical company focused on developing precise medicines that target specific drivers of cancer using a structure-based drug design approach. OnKure's pipeline includes tumor-agnostic drug candidates, aiming to maximize effectiveness and safety. It is currently developing bocodepsin (OKI-179), an oral inhibitor for hematological and solid tumors, and OKI-219, a selective inhibitor for PI3K alpha H1047R. 

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.